Skip to main content
45°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gracell Biotechnologies Inc.
Gracell Biotechnologies Acquisition Completed
February 22, 2024
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
February 20, 2024
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
January 29, 2024
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
December 26, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
December 21, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
December 11, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
November 27, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
November 16, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
November 13, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program
November 08, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition
November 02, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
November 01, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 31, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
October 30, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
September 27, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
September 26, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
September 19, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
September 14, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
August 24, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
August 14, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
July 31, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference
July 31, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium
June 20, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
June 10, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Participate in Jefferies Healthcare Conference
May 24, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd
May 15, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update
May 15, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
May 10, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023
May 02, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022
April 25, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Tickers
GRCL
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.